|
1）医薬産業政策研究所．アンメット・メディカル・ニーズに対する医薬品の開発・承認状況．政策研ニュース．2011; 34
|
|
|
|
|
2）Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994; 264: 1336-40
|
|
|
|
|
3）Citron M, Oltersdorf T, Haass C, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimerʼs disease increases beta-protein production. Nature. 1992; 360: 672-4
|
|
|
|
|
4）Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimerʼs disease: progress and problems on the road to therapeutics. Science. 2002; 297: 353-6
|
|
|
|
|
|
5）Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alz-heimerʼs disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008; 372: 216-23
|
|
|
|
|
|
6）Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009; 73: 2061-70
|
|
|
|
|
|
7）Jokinen P, Scheinin N, Aalto S, et al. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinsonʼs disease with and without dementia. Parkinsonism Relat Disord. 2010; 16: 666-70
|
|
|
|
|
|
8）Tayeb HO, Murray ED, Price BH, et al. Bapineuzumab and solanezumab for Alzheimerʼs disease: is the ʻamyloid cascade hypothesisʼ still alive? Expert Opin Biol Ther. 2013; 13: 1075-84
|
|
|
|
|
|
9）Schor NF. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol. 2011; 69: 237-9
|
|
|
|
|
|
10）Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009; 302: 2557-64
|
|
|
|
|
|
11）Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002; 416: 535-9
|
|
|
|
|
|
12）McLaurin J, Golomb R, Jurewicz A, et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem. 2000; 275: 18495-502
|
|
|
|
|
|
13）McLaurin J, Kierstead ME, Brown ME, et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006; 12: 801-8
|
|
|
|
|
|
14）Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011; 77: 1253-62
|
|
|
|
|
|
15）Faux NG, Ritchie CW, Gunn A, et al. PBT2 rapidly improves cognition in Alzheimerʼs Disease: additional phase II analyses. J Alzheimers Dis. 2010; 20: 509-16
|
|
|
|
|
|
16）Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimerʼs disease. N Engl J Med. 2012; 367: 795-804
|
|
|
|
|
|
17）Yagi T, Ito D, Okada Y, et al. Modeling familial Alzheimerʼs disease with induced pluripotent stem cells. Hum Mol Genet. 2011; 20: 4530-9
|
|
|
|
|
|
18）Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimerʼs disease using induced pluripotent stem cells. Nature. 2012; 482: 216-20
|
|
|
|
|
|
19）伊東大介，八木拓也，鈴木則宏．iPS細胞をもちいた高齢発症神経変性疾患研究の可能性．Brain and Nerve. 2013; 65: 283-8
|
|
|
|
|
20）Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimerʼs disease. Ann Neurol. 1996; 39: 62-70
|
|
|
|
|
|
21）Callaway E. Alzheimerʼs drugs take a new tack. Nature. 2012; 489: 13-4
|
|
|
|
|
|
22）Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012; 335: 1503-6
|
|
|
|
|
|
23）Deschaintre Y, Richard F, Leys D, et al. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009; 73: 674-80
|
|
|
|
|